```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:20:47 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 3 Feb 2006  VOL 144 ISS 7
FILE LAST UPDATED: 2 Feb 2006  (20060202/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que
L5                STR
```




```
VAR G1=CH/11
VAR G2=ME/14/17/X/CN/NH2
VAR G3=CH/19
VAR G4=CH3/OH/17/SH/23/26/N/X/CN
VAR G5=66/32/33/34
VAR G20=O/S/N/26/X/CN/AK/CY
NODE ATTRIBUTES:
NSPEC   IS RC     AT  34
DEFAULT MLEVEL IS ATOM
```

```
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  33

STEREO ATTRIBUTES: NONE
L7          533 SEA FILE=REGISTRY SSS FUL L5
L8          350 SEA FILE=REGISTRY ABB=ON  PLU=ON  P38/BI
L9          128 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND KINASE
L10          47 SEA FILE=REGISTRY ABB=ON  PLU=ON  (MITOGEN(W)ACTIVATED OR
                MAP)(L)KINASE(L)(P38 OR P(W)38)
L11          18 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L12       32869 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 OR L10 OR P38 OR P(W)38 OR
                MAP(2A)KINASE OR MITOGEN(W)ACTIVATED
L13           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND L12
L14          13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND (PAIN OR ?ACHE? OR
                ?EDEM? OR ?ANALGES? OR ?FEVER? OR ?IMMUNE? OR HIV? OR HTLV OR
                ?CANCER? OR ?NEOPLAS? OR ?MALIG? OR ?TUMOR? OR ?PROLIVER? OR
                ?ANGIOGEN? OR ?NEURODE? OR ?VIRAL? OR ?INFLAM? OR ?ASTHM? OR
                ?DIABET? OR (BLOOD OR BLD)(W)SUGAR OR BOWEL(W)DISEASE)
L15           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND (?PULMON? OR ?OSTEOPOR
                ? OR BONE(W)LOSS OR ?DEMENT? OR ?SENIL? OR ?ALZHEM? OR ?PSORI?
                OR ?ARTHRI? OR ?GOUT?)
L16           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 AND (L14 OR L15)


=>
=>

=> d ibib abs hitstr l16 1-4

L16  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:160831  HCAPLUS
DOCUMENT NUMBER:          142:261564
TITLE:                    Heteroaryl-substituted pyrrolo-triazine compounds
                          useful as kinase inhibitors, particularly p38
                          kinases, and their preparation, pharmaceutical
                          compositions, and use
INVENTOR(S):              Leftheris, Katerina; Wrobleski, Stephen T.; Dyckman,
                          Alaric J.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S.
                          Ser. No. 420,399.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2005043306         A1    20050224    US 2003-678388          20031003
     US 2004082582         A1    20040429    US 2003-420399          20030422
     WO 2005037838         A1    20050428    WO 2004-US30829         20040921
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
```

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-374938P P 20020423
US 2003-420399 A2 20030422
US 2003-678388 A 20031003

OTHER SOURCE(S): MARPAT 142:261564

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, are surprisingly advantageous as **p38** kinase inhibitors [wherein X = O, OCO, S, halo, CN, absent, etc.; Z = (un)substituted heteroaryl; R1, R5 = independently H, alkyl, substituted alkyl, etc.; R2 = H, alkyl; R3 = H, Me, CF3, OMe, halo, CN, NH2, NH(Me); R4 = (un)substituted alk(en/yn)yl, heterocyclyl, hetero/aryl, etc.; R6 = at each occurrence independently halo, CF3, OCF3, CN, (un)substituted alkyl, sulfonamido, etc.; m = 0-3]. Compds. I have shown activity as inhibitors of **p38**.alpha./β enzymes and TNF-α. For instance, II was prepared in 7 steps by (a) acylation of 4-methyl-3-nitrobenzoyl chloride with tert-Bu carbazate; (b) Boc-deprotection; (c) cyclization of the acyl hydrazide with MeC(OEt)3, (d) hydrogenation of the nitro intermediate over Pd/C; (e) coupling of the amine with chloride III (preparation given), (f) saponification of the ester; and (g) reaction with n-PrNH2.

IT **845884-78-8P 845884-79-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of heteroaryl pyrrolotriazine compds. as **p38** kinase inhibitors)

RN 845884-78-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-(1H-1,2,4-triazol-3-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 845884-79-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-(1H-

1,2,4-triazol-3-yl)phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **845884-68-6P 845884-71-1P 845884-72-2P**
845884-73-3P 845884-74-4P 845884-75-5P
845884-84-6P 845884-85-7P 845884-86-8P
845884-87-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl pyrrolotriazine compds. as **p38** kinase inhibitors)

RN 845884-68-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 845884-71-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 845884-72-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-N-(1-methylethyl)-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 845884-73-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(5S)-4,5-dihydro-5-methyl-1,3,4-oxadiazol-2-yl]-2-methylphenyl]amino]-5-methyl-N-(1-methylenepropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845884-74-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(5S)-4,5-dihydro-5-methyl-1,3,4-oxadiazol-2-yl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845884-75-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1-ethylpropyl)-5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 845884-84-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 845884-85-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 845884-86-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845884-87-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



IT **165245-96-5 179800-23-8**
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; preparation of heteroaryl pyrrolotriazine compds. as **p38** kinase inhibitors)
RN 165245-96-5 HCAPLUS
CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 179800-23-8 HCAPLUS
CN Kinase (phosphorylating), protein p38β (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **845884-69-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heteroaryl pyrrolotriazine compds. as **p38** kinase inhibitors)
RN 845884-69-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **845884-88-0**, 4-(5-Cyano-2-methylphenylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl pyrrolotriazine compds. as **p38** kinase inhibitors)
RN 845884-88-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-cyano-2-methylphenyl)amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:875265 HCAPLUS
DOCUMENT NUMBER: 139:364963
TITLE: Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors, particularly **p38** kinases, and their preparation, pharmaceutical compositions, and use
INVENTOR(S): Dyckman, Alaric; Leftheris, Katerina; Hynes, John
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003091229	A1	20031106	WO 2003-US12420		20030418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1503996	A1	20050209	EP 2003-718493		20030418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005529890	T2	20051006	JP 2003-587789		20030418
US 2003232831	A1	20031218	US 2003-420445		20030422
NO 2004004592	A	20041119	NO 2004-4592		20041025
PRIORITY APPLN. INFO.:			US 2002-374907P	P	20020423
			WO 2003-US12420	W	20030418

OTHER SOURCE(S): MARPAT 139:364963
GI



I



II



III

AB Title compds. I and their pharmaceutically acceptable salts, prodrugs, and solvates, are surprisingly advantageous as **p38** kinase inhibitors [wherein: A = (un)substituted Ph; W = (un)substituted azine, 1,2-, 1,3-, or 1,4-diazine, or 1,2,4-triazine ring; R1, R4 = H, (un)substituted alkyl, OH or derivs., SH or derivs, CO2H or derivs., NH2 or derivs., halo, NO2, cyano; R2 = H, alkyl; R3 = H, Me, CF3, MeO, halo, cyano, NH2, or NHMe, preferably Me]. Seventeen specific compds. I and various intermediates were prepared Compds. I selectively inhibited human **p38** α/β isoenzymes in vitro with IC50 values below 500 nM. For instance, the pyrrolotriazinone ester II underwent reduction of the ester to an alc. with LAH (86%), reoxidn. to an aldehyde with Jones reagent (65%), Grignard reaction of the aldehyde with PhMgBr and reoxidn. of the resultant alc. with Jones reagent (66% combined), chlorination of the ring oxo group with POCl3 (100%), and aminolysis of the chloride with 3-amino-4-methylbenzoic acid (88%), to give title compound III.

IT **621685-40-3P 621685-41-4P 621685-42-5P**
621685-44-7P 621685-45-8P 621685-46-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl ketone pyrrolotriazine compds. as **p38** kinase inhibitors)

RN 621685-40-3 HCAPLUS

CN Carbamic acid, [3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 621685-41-4 HCAPLUS
CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-N-(2-methoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 621685-42-5 HCAPLUS
CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 621685-44-7 HCAPLUS

CN Methanone, [4-[(5-ethyl-2-methylphenyl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]phenyl- (9CI) (CA INDEX NAME)



RN 621685-45-8 HCAPLUS
CN Methanone, [5-methyl-4-[(2-methyl-5-propylphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-6-yl]phenyl- (9CI) (CA INDEX NAME)



RN 621685-46-9 HCAPLUS
CN Methanone, [5-methyl-4-[[2-methyl-5-(1-methylethyl)phenyl]amino]pyrrolo[2,1-f][1,2,4]triazin-6-yl]phenyl- (9CI) (CA INDEX NAME)



IT **621685-60-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aryl ketone pyrrolotriazine compds. as

p38 kinase inhibitors)
RN 621685-60-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-carboxy-2-methylphenyl)amino]-5-methyl-, 6-ethyl ester (9CI) (CA INDEX NAME)



IT **165245-96-5**, **p38** Kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aryl ketone pyrrolotriazine compds. as **p38** kinase inhibitors)
RN 165245-96-5 HCAPLUS
CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:875173 HCAPLUS
DOCUMENT NUMBER: 139:381511
TITLE: Pyrrolotriazine aniline compounds useful as kinase inhibitors, particularly **p38** kinases, and their preparation, pharmaceutical compositions, and use as **antiinflammatory** agents
INVENTOR(S): Dyckman, Alaric; Hynes, John; Leftheris, Katherina; Liu, Chunjian; Wrobleski, Stephen T.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090912	A1	20031106	WO 2003-US12426	20030415
WO 2003090912	C2	20040108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2483164		AA	20031106	CA 2003-2483164		20030415
EP 1497019		A1	20050119	EP 2003-724157		20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003009669		A	20050301	BR 2003-9669		20030415
JP 2005523338		T2	20050804	JP 2003-587532		20030415
NO 2004004560		A	20041110	NO 2004-4560		20041022
PRIORITY APPLN. INFO.:				US 2002-374938P	P	20020423
				WO 2003-US12426	W	20030415

OTHER SOURCE(S): MARPAT 139:381511

GI



I



II



III

AB Title compds. I and their enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs, and solvates are useful as **p38** kinase inhibitors [wherein: A = certain substituted Ph rings, particularly bearing various carboxamide and sulfonamide substituents; X = O, OCO, S, S(O), SO2, CO, CO2, (un)substituted NH, NHCO, NHCONH, NHCO2, NHSO2, NHSO2NH, SO2NH, or CONH, halo, NO2, cyano, or bond; R1, R5 = H, (un)substituted alkyl, OH or derivs., SH or derivs, CO2H or derivs., NH2 or derivs., halo, NO2, cyano; R2 = H, alkyl; R3 = H, Me, CF3, MeO, halo, cyano, NH2, or NHMe; R4 = H (with provisos), (un)substituted alk(en/yn)yl, (hetero)aryl, (hetero)cycloalkyl, or absent]. Over 300 specific compds. I and various intermediates were prepared Compds. I selectively inhibited human **p38**.alpha./β isoenzymes and TNF-α in vitro (no data). For instance, 3-amino-4-methylbenzoic acid was amidated quant. with cyclopropylamine using EDC and DMAP in DMF. The pyrrolotriazinone ester II was then chlorinated at the ring oxo group with POCl3 (100%). Aminolysis of the resulting chloride with the benzamide product from the first step gave 80% invention compound III.

IT **427878-38-4P 427878-44-2P 427878-45-3P 623152-11-4P 623152-13-6P 623152-14-7P**

623152-15-8P 623152-16-9P 623152-17-0P
623152-18-1P 623152-24-9P 623152-25-0P
623152-26-1P 623152-27-2P 623152-34-1P
623152-35-2P 623152-36-3P 623152-37-4P
623152-38-5P 623152-39-6P 623152-40-9P
623152-41-0P 623152-42-1P 623152-43-2P
623152-44-3P 623152-45-4P 623152-46-5P
623152-47-6P 623152-62-5P 623152-68-1P
623152-71-6P 623152-72-7P 623152-73-8P
623152-74-9P 623152-75-0P 623152-76-1P
623152-77-2P 623152-78-3P 623152-79-4P
623152-80-7P 623152-82-9P 623153-08-2P
623153-09-3P 623153-10-6P 623153-11-7P
623153-12-8P 623153-13-9P 623153-14-0P
623153-15-1P 623153-16-2P 623153-17-3P
623153-18-4P 623153-19-5P 623153-20-8P
623153-21-9P 623153-22-0P 623153-23-1P
623153-24-2P 623153-25-3P 623153-26-4P
623153-27-5P 623153-28-6P 623153-29-7P
623153-30-0P 623153-31-1P 623153-32-2P
623153-33-3P 623153-34-4P 623153-35-5P
623153-37-7P 623153-39-9P 623153-40-2P
623153-41-3P 623153-44-6P 623153-45-7P
623153-46-8P 623153-47-9P 623153-48-0P
623153-51-5P 623153-52-6P 623153-53-7P
623153-54-8P 623153-55-9P 623153-56-0P
623153-57-1P 623153-58-2P 623153-60-6P
623153-61-7P 623153-62-8P 623153-63-9P
623153-64-0P 623153-65-1P 623153-66-2P
623153-67-3P 623153-68-4P 623153-69-5P
623153-70-8P 623153-71-9P 623153-72-0P
623153-73-1P 623153-74-2P 623153-75-3P
623153-76-4P 623153-77-5P 623153-78-6P
623153-79-7P 623153-80-0P 623153-81-1P
623153-82-2P 623153-83-3P 623153-84-4P
623153-85-5P 623153-86-6P 623153-87-7P
623153-88-8P 623153-89-9P 623153-90-2P
623153-91-3P 623153-92-4P 623153-93-5P
623153-94-6P 623153-95-7P 623153-96-8P
623153-97-9P 623153-98-0P 623153-99-1P
623154-00-7P 623154-01-8P 623154-02-9P
623154-03-0P 623154-04-1P 623154-05-2P
623154-06-3P 623154-07-4P 623154-08-5P
623154-09-6P 623154-10-9P 623154-11-0P
623154-12-1P 623154-13-2P 623154-14-3P
623154-15-4P 623154-16-5P 623154-17-6P
623154-18-7P 623154-19-8P 623154-20-1P
623154-21-2P 623154-22-3P 623154-23-4P
623154-24-5P 623154-26-7P 623154-28-9P
623154-30-3P 623154-31-4P 623154-32-5P
623154-34-7P 623154-36-9P 623154-37-0P
623154-38-1P 623154-39-2P 623154-40-5P
623154-41-6P 623154-42-7P 623154-43-8P
623154-44-9P 623154-45-0P 623154-46-1P
623154-47-2P 623154-48-3P 623154-49-4P
623154-50-7P 623154-51-8P 623154-52-9P
623154-54-1P 623154-55-2P 623154-57-4P
623154-58-5P 623154-59-6P 623154-60-9P
623154-63-2P 623154-64-3P 623154-65-4P
623154-66-5P 623154-67-6P 623154-68-7P

623154-69-8P 623154-70-1P 623154-71-2P
623154-72-3P 623154-73-4P 623154-74-5P
623154-75-6P 623154-76-7P 623154-77-8P
623154-78-9P 623154-79-0P 623154-80-3P
623154-81-4P 623154-82-5P 623154-83-6P
623154-84-7P 623154-85-8P 623154-86-9P
623154-87-0P 623154-88-1P 623154-89-2P
623154-90-5P 623154-91-6P 623154-92-7P
623154-93-8P 623154-94-9P 623154-95-0P
623154-96-1P 623154-97-2P 623154-98-3P
623154-99-4P 623155-00-0P 623155-03-3P
623155-04-4P 623155-05-5P 623155-08-8P
623155-09-9P 623155-13-5P 623155-14-6P
623155-15-7P 623155-17-9P 623155-18-0P
623156-24-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolotriazine aniline compds. as **p38** kinase inhibitors)

RN 427878-38-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-44-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-45-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623152-11-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623152-13-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-14-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-15-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 623152-16-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-

[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623152-17-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623152-18-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-24-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623152-25-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(3-hydroxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-26-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623152-27-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-[(1R)-2-hydroxy-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623152-34-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-ethoxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-35-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-ethoxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-36-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-ethoxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-phenylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-37-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-hydroxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-phenylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-38-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]phenyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-39-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-40-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623152-41-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(2-thiazolylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623152-42-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[4-(1,1-dimethylethyl)-2-thiazolyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-43-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[(5-methyl-2-thiazolyl)amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623152-44-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX

NAME)



RN 623152-45-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1,3,4-thiadiazol-2-ylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623152-46-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(2-oxazolylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623152-47-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1H-pyrazol-3-ylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623152-62-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-cyanoethyl)-4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-68-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 623152-71-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-72-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623152-73-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-74-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 623152-75-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623152-76-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-

[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(3-ethoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-77-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-[3-(dimethylamino)propyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-78-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 623152-79-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 623152-80-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(2-hydroxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-82-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 623153-08-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(4-morpholinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-09-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[3-(4-morpholinyl)phenyl]amino]carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-10-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(4-pyridinylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 623153-11-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(2-pyridinylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-12-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-13-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(1,3-dimethyl-1H-pyrazol-5-yl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-14-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 623153-15-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[(1-phenyl-1H-pyrazol-5-yl)amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-16-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 623153-17-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[3-fluoro-5-(4-morpholinyl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-18-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-fluoro-5-(4-morpholinyl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-19-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(4-methyl-1-piperazinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-20-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[[3-(4-methyl-1-piperazinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-21-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-22-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[[3-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-23-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[3-(1H-imidazol-1-yl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-24-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1H-imidazol-1-yl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-25-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(2-oxo-1-pyrrolidinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-26-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[[3-(2-oxo-1-pyrrolidinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-27-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[2-(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-28-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[2-

(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-29-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[2-(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-30-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-31-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-32-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-33-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-

[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-34-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-35-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-37-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-hydroxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-39-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-40-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-41-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-44-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623153-45-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 623153-46-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-47-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 623153-48-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-

methyl- (9CI) (CA INDEX NAME)



RN 623153-51-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-52-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-methoxy-1-methylethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-53-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-54-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-55-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-56-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(3-methylbenzoyl)amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-57-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-58-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-60-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-(2,3-dihydroxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-61-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-fluorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-62-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-ethynylbenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-63-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-methoxybenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-64-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-chlorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-65-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-66-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(trifluoromethoxy)benzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-67-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(4-methylbenzoyl)amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-68-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-69-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-methoxybenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-70-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(2,4-difluorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-71-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(2,4-dimethoxybenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-72-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3,5-dichlorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-73-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3,5-bis(trifluoromethyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-74-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(2,6-dichlorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-75-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(benzoylamino)-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-76-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(4-pyridinylcarbonyl)amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-77-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-(dimethylamino)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-78-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(acetylamino)-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-79-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[(2-methyl-1-oxopropyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-80-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopentylcarbonyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-81-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(benzoylamino)-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-82-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[(4-pyridinylcarbonyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-83-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3,5-dimethyl-4-isoxazolyl)carbonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-84-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-85-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(1,3-benzodioxol-5-ylcarbonyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-86-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3,4-dimethoxybenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-87-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[3-(trifluoromethoxy)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-88-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[(pyrazinylcarbonyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-89-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(1H-benzimidazol-5-ylcarbonyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-90-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(2,3-dihydro-5-benzofuranyl)carbonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-91-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-fluorobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-92-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3,4-difluorobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-93-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-4-(trifluoromethoxy)benzoyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-94-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[4-(methylsulfonyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-95-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-4-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-96-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-97-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623153-98-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-99-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-(2-hydroxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-00-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(1H-pyrazol-1-yl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-01-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(1H-pyrazol-1-yl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-02-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(4-methyl-1-piperazinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-03-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(4-methyl-1-piperazinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-04-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[3-(1H-imidazol-1-yl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-05-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-(1H-imidazol-1-

yl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-06-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(2-oxo-1-pyrrolidinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-07-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(2-oxo-1-pyrrolidinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-08-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(1-piperazinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-09-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(1-piperazinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-10-9 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-11-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(acetylamino)-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-12-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(acetylamino)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-13-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1-oxopropyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-14-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(1-oxopropyl)amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-15-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(ethoxycarbonyl)amino]-2-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-16-5 HCAPLUS
CN Carbamic acid, [3-[[6-[[[(1S)-2-methoxy-1-methylethyl]amino]carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623154-17-6 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1S)-1-methylpropyl]amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623154-18-7 HCAPLUS
CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-19-8 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-20-1 HCAPLUS
CN Carbamic acid, [3-[[6-[[(2-hydroxyethyl)amino]carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-21-2 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-22-3 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, propyl ester (9CI) (CA INDEX NAME)



RN 623154-23-4 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 623154-24-5 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)



RN 623154-26-7 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 623154-28-9 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)



RN 623154-30-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyacetyl)amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-31-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyacetyl)amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-32-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-34-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-36-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623154-37-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-38-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-39-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623154-40-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 623154-41-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[2-(methylamino)-2-oxoethyl]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-42-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[2-(methylamino)-2-oxoethyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-43-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[2-(methylamino)-2-oxoethyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-44-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[(1-oxopropyl)amino]carbonyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-45-0 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-46-1 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-47-2 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 623154-48-3 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 623154-49-4 HCAPLUS
CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-50-7 HCAPLUS
CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-51-8 HCAPLUS
CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 623154-52-9 HCAPLUS
CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 623154-54-1 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(methylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-55-2 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(methylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 623154-57-4 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-58-5 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-59-6 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 623154-60-9 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 623154-63-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(cyclopropylamino)carbonyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-64-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(cyclopropylamino)carbonyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-65-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(methylamino)carbonyl]amino]carbonyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-66-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(acetylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-67-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[(methoxycarbonyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-68-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(acetylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-69-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[(2-methyl-1-oxopropyl)amino]carbonyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-70-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(cyclopropylcarbonyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-71-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(cyclopropylcarbonyl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-72-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[(1-oxopropyl)amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-73-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[(ethoxycarbonyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-74-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-75-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(acetylamino)methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-76-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[(methoxyacetyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-77-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[[(1-oxopropyl)amino]methyl]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-78-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[(4-cyanobenzoyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-79-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-80-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-81-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-N-(2-hydroxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-82-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[(methoxyacetyl)amino]methyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-83-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(methoxyacetyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-84-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-hydroxyethyl)-4-[[5-[[(methoxyacetyl)amino]methyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-85-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[(1-oxopropyl)amino]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-86-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[(1-oxopropyl)amino]methyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-87-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-hydroxyethyl)-5-methyl-4-[[2-methyl-5-[[(1-oxopropyl)amino]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-88-1 HCAPLUS
CN Carbamic acid, [[3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-89-2 HCAPLUS
CN Carbamic acid, [[4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-90-5 HCAPLUS
CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl-, 2-formylhydrazide (9CI) (CA INDEX NAME)



RN 623154-91-6 HCAPLUS
CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl-, 2-benzoylhydrazide (9CI) (CA INDEX NAME)



RN 623154-92-7 HCAPLUS
CN Hydrazinecarboxylic acid, 2-[3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-93-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[(2-oxo-2-phenylethyl)amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623154-94-9 HCAPLUS
CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl-, 2-acetylhydrazide (9CI) (CA INDEX NAME)



RN 623154-95-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(aminocarbonyl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-96-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-acetyl-2-methylphenyl)amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-97-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-acetyl-2-methylphenyl)amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-98-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-acetyl-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-99-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(fluoroacetyl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623155-00-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(ethoxyacetyl)-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-03-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1H-pyrrol-1-ylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623155-04-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-N-(1-methylethyl)-4-[[2-methyl-5-[(1H-pyrrol-1-ylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623155-05-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(1H-

pyrrol-1-ylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623155-08-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(2,5-dimethyl-1H-pyrrol-1-yl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623155-09-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(2,5-dimethyl-1H-pyrrol-1-yl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623155-13-5 HCAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[[5-methyl-6-(1-oxo-2-butynyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 623155-14-6 HCAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[[5-methyl-6-(1-oxo-2-propynyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 623155-15-7 HCAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[[5-methyl-6-(1-oxobutyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 623155-17-9 HCAPLUS
CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-N-ethyl-4-methyl- (9CI) (CA INDEX NAME)



RN 623155-18-0 HCAPLUS
CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623156-24-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(2,5-dimethyl-1H-pyrrol-1-yl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



IT **427878-34-0P 427878-56-6P 427878-58-8P**
427878-59-9P 621685-60-7P 623155-23-7P
623155-39-5P 623155-41-9P 623155-43-1P
623155-45-3P 623155-46-4P 623155-47-5P
623155-58-8P 623155-61-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrolotriazine aniline compds. as **p38** kinase inhibitors)

RN 427878-34-0 HCAPLUS

CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl- (9CI) (CA INDEX NAME)



RN 427878-56-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-58-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-59-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 621685-60-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-carboxy-2-methylphenyl)amino]-5-methyl-, 6-ethyl ester (9CI) (CA INDEX NAME)



RN 623155-23-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-7-formyl-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-39-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[[[2-(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-41-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]-, ethyl ester (9CI) (CA

INDEX NAME)



RN 623155-43-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-45-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623155-46-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-

methylphenyl)amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623155-47-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(carboxymethyl)-2-methylphenyl]amino]-5-methyl-, 6-ethyl ester (9CI) (CA INDEX NAME)



RN 623155-58-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2-fluoro-1,1-dimethoxyethyl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623155-61-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(2-ethoxy-1-hydroxyethyl)-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



IT **165245-96-5**, **p38** Kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrrolotriazine aniline compds. as **p38** kinase inhibitors)
RN 165245-96-5 HCAPLUS
CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **427877-76-7 427878-02-2 623155-62-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of pyrrolotriazine aniline compds. as **p38** kinase inhibitors)
RN 427877-76-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-02-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623155-62-4 HCAPLUS
CN Benzoic acid, 4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:391720 HCAPLUS
DOCUMENT NUMBER: 136:386144
TITLE: Preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivatives for use in treating **p38** kinase-associated conditions
INVENTOR(S): Leftheris, Katerina; Barrish, Joel; Hynes, John; Wrobleski, Stephen T.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040486	A2	20020523	WO 2001-US49982	20011107
WO 2002040486	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2429628	AA	20020523	CA 2001-2429628		20011107
AU 2002032760	A5	20020527	AU 2002-32760		20011107
EE 200300227	A	20031015	EE 2003-227		20011107
EP 1363910	A2	20031126	EP 2001-992298		20011107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004522713	T2	20040729	JP 2002-543494		20011107
NZ 525334	A	20050729	NZ 2001-525334		20011107
BR 2001015446	A	20050809	BR 2001-15446		20011107
BG 107750	A	20040130	BG 2003-107750		20030421
ZA 2003003786	A	20040816	ZA 2003-3786		20030515
NO 2003002229	A	20030716	NO 2003-2229		20030516
PRIORITY APPLN. INFO.:			US 2000-249877P	P	20001117
			US 2001-310561P	P	20010807
			WO 2001-US49982	W	20011107

OTHER SOURCE(S): MARPAT 136:386144

GI



I



II



III

AB Title compds. I [R3 = H, Me, perfluoromethyl, MeO, halo, cyano, NH2; X = O, OC(O), S, S(O), SO2, C(O), CO2, amino, aminoacyl, etc. or X is absent;

Z = O, S, N, and CR20, wherein when Z = CR20 said carbon atom may form an (un)(un)substituted bicyclic aryl or heteroaryl with R4 and R5; R1 = H, CH3, OH, OCH3, SH, SCH3, acyloxy, etc.; R2 = H, alkyl, alkenyl, aryl, heteroaryl, etc.; R4 = (un)substituted aryl, heteroaryl, bicyclic 7-11 membered (un)saturated carbocyclic or heterocyclic ring; R5 = H, alkyl, etc. or alternatively, R4 and R5 taken together with Z form an (un)substituted bicyclic 7-11 membered aryl or heteroaryl; R6 = H, alkyl, aryl, heterocyclo, etc.; R20 = H, alkyl, etc. with some provisions] were prepared Over 150 compds. were disclosed. For instance, 1-Amino-3-methylpyrrole-2,4-dicarboxylic acid di-Me ester was prepared from the parent pyrrole (preparation given) and diphenylphosphorylhydroxylamine and reacted with formamide (165°C, 6 h) to give intermediate pyrrolo[2,1-f][1,2,4]triazine II in 90% yield. II was converted to the imino-chloride (POCl3) and treated with indoline to give example compound III. I are inhibitors of **p38** kinase and are useful for the treatment of **inflammatory** disorders.

IT **427878-02-2P**, N-Ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating **p38** kinase-associated conditions)

RN 427878-02-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



IT **310442-50-3P**, 4-[[3-[[Butylamino]sulfonyl]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester **310442-52-5P**, 4-[[3-[Acetylamino]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester **310442-57-0P**, 4-[[1-Acetyl-2,3-dihydro-1H-indol-6-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester **310442-84-3P**, 4-[[6-[Acetylamino]-3-pyridinyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester **310443-13-1P**, 4-[2,3-Dihydro-2-oxo-1H-indol-3-yl]-5-methoxypyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester **310443-27-7P**, 4-[2,3-Dihydro-5-[[[2-hydroxyethyl]amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester **310444-01-0P**, 1,3-Dihydro-3-[5-methoxy-6-[[4-[4-methyl-1-piperazinyl]butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2H-indol-2-one **310444-03-2P**,

1,3-Dihydro-3-[5-methoxy-6-[[4-[4-morpholinyl]butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2H-indol-2-one **310444-49-6P**, 2-Methyl-5-[[5-methyl-6-[3-[2H-1,2,3-triazol-2-yl]propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenol **427877-55-2P** **427877-58-5P**, 4-[[5-[[Ethylamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester **427877-67-6P**, N-[2,2-Dimethylpropyl]-N-methyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-68-7P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-methylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-69-8P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-70-1P**, N-[2,2-Dimethylpropyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-71-2P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-72-3P**, N-[1,1-Dimethylethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-73-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-[2-methoxyethyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-75-6P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-76-7P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-80-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-[4-pyridinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-81-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-[1-piperidinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-82-5P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-[4-morpholinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-87-0P**, N-[2-[4-Fluorophenyl]ethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-90-5P**, N-[2-1H-Indol-3-ylethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-91-6P**, N-Butyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-93-8P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-methylbutyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-96-1P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-phenoxyethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-98-3P**, N-Ethyl-N-methyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-99-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2,2,2-trifluoroethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-00-0P**, N-[2-Fluoroethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-03-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2,2,3,3,3-pentafluoropropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-04-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(dimethylamino)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-10-2P**, N-[(1S)-1-Cyano-2-phenylethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-

f][1,2,4]triazine-6-carboxylic acid amide **427878-17-9P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-18-0P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-20-4P**, N-N-[1-[4-Fluorophenyl]ethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-27-1P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester **427878-28-2P**, N-Ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-29-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-propyl-5-[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-30-6P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-methylpropyl]-5-[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-31-7P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-phenylethyl]-5-[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-32-8P 427878-33-9P**, N-Ethyl-5-methyl-4-[[2-methyl-5-[[[3-[trifluoromethyl]phenyl]amino]carbonyl]phenyl]amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-35-1P**, 4-[[5-[[[4-Cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-36-2P**, 5-Methyl-4-[[2-methyl-5-[[phenylamino]carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-37-3P**, 4-[[5-[[[4-Cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-38-4P**, N-Ethyl-4-[[5-[[[3-fluorophenyl]sulfonyl]amino]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-44-2P**, 4-[[5-[[[3-Fluorophenyl]sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-45-3P**, 4-[[5-[[[3-Fluorophenyl]sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-46-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester **427878-47-5P**, N-Ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-48-6P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-49-7P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[1-methylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-52-2P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-[4-morpholinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-53-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-[1-piperidinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-54-4P**, N-[2-[Dimethylamino]ethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-55-5P**, 4-[[5-[[[Ethylamino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-60-2P**, 5-Methyl-4-[[2-methyl-5-[[[phenylamino]carbonyl]amino]phenyl]amino]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-61-3P**, 5-Methyl-4-[[2-methyl-5-[[[[3-methylphenyl]amino]carbonyl]amino]phenyl]ami

no]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-62-4P**, 4-[[5-[[[[4-Cyanophenyl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-63-5P**, 4-[[5-[[[[2,3-Dichlorophenyl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-64-6P**, 4-[[5-[[[[4-Fluorophenyl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-65-7P**, 5-Methyl-4-[[2-methyl-5-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-66-8P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-67-9P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-68-0P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating **p38** kinase-associated conditions)

RN 310442-50-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-[(butylamino)sulfonyl]phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-52-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-(acetylamino)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-57-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-84-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[6-(acetylamino)-3-pyridinyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310443-13-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 310443-27-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-5-[[(2-hydroxyethyl)amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-01-0 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-methyl-1-piperazinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 310444-03-2 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-morpholinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 310444-49-6 HCAPLUS
CN Phenol, 2-methyl-5-[[5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 427877-55-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 427877-58-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-

[(ethylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 427877-67-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 427877-68-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)-(9CI) (CA INDEX NAME)



RN 427877-69-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 427877-70-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-71-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427877-72-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1,1-dimethylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-73-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-75-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-76-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-80-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-

pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-81-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-82-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-87-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-90-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 427877-91-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-93-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-

[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylbutyl)-
(9CI) (CA INDEX NAME)



RN 427877-96-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenoxyethyl)-
(9CI) (CA INDEX NAME)



RN 427877-98-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA
INDEX NAME)



RN 427877-99-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 427878-00-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-fluoroethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-03-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)



RN 427878-04-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-10-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-1-cyano-2-phenylethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-17-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-18-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-20-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[1-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-27-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-28-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-29-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-propyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-30-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-methylpropyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-31-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-phenylethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-32-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 427878-02-2
CMF C19 H22 N6 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 427878-33-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 427878-35-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(4-cyanophenyl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-36-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(phenylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-37-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(4-cyanophenyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-

phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-38-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-44-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-45-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3-

fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-46-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-47-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 427878-48-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-49-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 427878-52-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427878-53-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427878-54-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 427878-55-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(ethylamino)carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-60-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[(phenylamino)carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-61-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-62-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-cyanophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-63-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-64-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-65-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-66-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-

[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 427878-67-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 427878-68-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylpropyl)-
(9CI) (CA INDEX NAME)



IT **427877-66-5P 427878-34-0P 427878-42-0P**
427878-56-6P, 5-Methyl-4-[[2-methyl-5-nitrophenyl]amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester **427878-58-8P**, 5-Methyl-4-[[2-methyl-5-nitrophenyl]amino]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-59-9P**, 4-[[5-Amino-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating **p38** kinase-associated conditions)

RN 427877-66-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-34-0 HCAPLUS
CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl- (9CI) (CA INDEX NAME)



RN 427878-42-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-56-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-58-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-59-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



IT **165245-96-5**, **p38** Kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating **p38** kinase-associated conditions)
RN 165245-96-5 HCAPLUS
CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> => d stat que l17
L5 STR









S @32









N @33 C @34




```
VAR G1=CH/11
VAR G2=ME/14/17/X/CN/NH2
VAR G3=CH/19
VAR G4=CH3/OH/17/SH/23/26/N/X/CN
VAR G5=66/32/33/34
VAR G20=O/S/N/26/X/CN/AK/CY
NODE ATTRIBUTES:
NSPEC   IS RC     AT  34
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  33

STEREO ATTRIBUTES: NONE
L7          533 SEA FILE=REGISTRY SSS FUL L5
L8          350 SEA FILE=REGISTRY ABB=ON  PLU=ON  P38/BI
L9          128 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND KINASE
L10          47 SEA FILE=REGISTRY ABB=ON  PLU=ON  (MITOGEN(W)ACTIVATED OR
                MAP)(L)KINASE(L)(P38 OR P(W)38)
L11          18 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L12       32869 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 OR L10 OR P38 OR P(W)38 OR
                MAP(2A)KINASE OR MITOGEN(W)ACTIVATED
L13           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND L12
L14          13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND (PAIN OR ?ACHE? OR
                ?EDEM? OR ?ANALGES? OR ?FEVER? OR ?IMMUNE? OR HIV? OR HTLV OR
                ?CANCER? OR ?NEOPLAS? OR ?MALIG? OR ?TUMOR? OR ?PROLIVER? OR
                ?ANGIOGEN? OR ?NEURODE? OR ?VIRAL? OR ?INFLAM? OR ?ASTHM? OR
                ?DIABET? OR (BLOOD OR BLD)(W)SUGAR OR BOWEL(W)DISEASE)
L15           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND (?PULMON? OR ?OSTEOPOR
                ? OR BONE(W)LOSS OR ?DEMENT? OR ?SENIL? OR ?ALZHEM? OR ?PSORI?
                OR ?ARTHRI? OR ?GOUT?)
L16           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 AND (L14 OR L15)
L17          10 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L13 OR L14 OR L15) NOT L16


=>
```

=>

=> d ibib abs hitstr l17 1-10

L17 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:638632 HCAPLUS
DOCUMENT NUMBER: 143:133402
TITLE: Preparation of disubstituted pyrrolo[2,1-f][1,2,4]triazine derivatives as and antiproliferative agents
INVENTOR(S): Gavai, Ashvinikumar V.; Han, Wen-Ching; Chen, Ping; Ruediger, Edward H.; Mastalerz, Harold; Fink, Brian E.; Norris, Derek J.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065266	A2	20050721	WO 2004-US43282	20041223
WO 2005065266	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005197339	A1	20050908	US 2004-19899	20041222
PRIORITY APPLN. INFO.:			US 2003-533361P P	20031229

OTHER SOURCE(S): MARPAT 143:133402
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R, R2 = independently (un)substituted hetero/aryl, heterocyclyl; R3, R4 = independently H, halo, (un)substituted alkyl, alkoxy, etc.; R5, R5a = H, halo, (un)substituted alkyl; X = O, NR5; Y = (C)n; N = 1-2; and their pharmaceutically acceptable salts, solvates, prodrugs and enantiomers] were prepared as inhibitors tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of **cancer** and other diseases. For example, a 7-step synthesis of II, starting from 4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine, is given. Most preferred compds. I had IC50 values between 0.01 and 0.1 μM in one or more HER1, HER2, and HER4 assays. I are useful for treating other diseases associated with signal transduction pathways operating through growth factor receptors.
IT **859205-94-0P**, 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-5-

methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester
859205-96-2P, (R)-3-[[[[4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamoyl]oxy]methyl]morpholine-4-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of disubstituted aminopyrrolotriazines as HER1, HER2 and HER4 inhibitors and antiproliferative agents)

RN 859205-94-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 859205-96-2 HCAPLUS
CN 4-Morpholinecarboxylic acid, 3-[[[[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:567104 HCAPLUS
DOCUMENT NUMBER: 143:97400
TITLE: A preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivatives, useful as antiproliferative agents
INVENTOR(S): Swaminathan, Shankar; Gavai, Ashvinikumar V.; Fan, Junying; Patel, Bharat P.; Norris, Derek J.; Corbett, Richard Michael; Zheng, Bin
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005058245	A2	20050630	WO 2004-US41920		20041210
WO 2005058245	A3	20050804			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005209454	A1	20050922	US 2004-8719		20041209
PRIORITY APPLN. INFO.:			US 2003-529347P	P	20031212
			US 2004-8719	A	20041209

OTHER SOURCE(S): MARPAT 143:97400
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivs. of formula I [wherein: R is aryl or heterocyclyl; R1 is alkyl; R2 is heterocyclyl], useful as inhibitors of tyrosine kinase activity of growth factor receptors such as HER1, HER2, and HER4 (no biol. data). For instance, (indazolylamino)pyrrolotriazine derivative II was prepared via Curtius rearrangement from (indazolylamino)pyrrolo[2,1-f][1,2,4]triazinecarboxylic acid derivative III, tert-Bu (R)-3-(hydroxymethyl)morpholine-4-carboxylate in the presence of diphenylphosphoryl azide and subsequent hydrolysis (yields: Curtius rearrangement: 82%, hydrolysis - 77%).

IT **714971-12-7P 856667-79-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivs. useful as antiproliferative agents)

RN 714971-12-7 HCAPLUS

CN 4-Morpholinecarboxylic acid, 3-[[[[[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856667-79-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:216796 HCAPLUS
DOCUMENT NUMBER: 142:316688
TITLE: Preparation of N-heterocycle derivatives as modulators of chemokine receptor activity
INVENTOR(S): Carter, Percy H.; Cherney, Robert J.; Batt, Douglas G.; Duncia, John V.; Gardner, Daniel S.; Ko, Soo S.; Srivastava, Anurag S.; Yang, Michael G.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 437 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021500	A1	20050310	WO 2004-US27196	20040820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005054627	A1	20050310	US 2004-923619	20040819

PRIORITY APPLN. INFO.: US 2003-496947P P 20030821
US 2004-923619 A 20040819

OTHER SOURCE(S): MARPAT 142:316688
GI



I



II

AB Title compds. I [Ring B = saturated or partially unsatd., (un)substituted cycloalkyl or heterocycle; X = O or S; Z = bond, NR8CO, NR8CS, NR8CONH, etc.; R1 = H, (un)substituted-alkyl, -alkenyl, -aryl, etc.; R2 = (un)substituted aryl or heterocycle; R8 = H, alkyl, cycloalkyl; R10 = H or (un)substituted alkyl; R11 = H, alkyl, etc.; R12 = H, alkyl, (un)substituted carbocycle; R13 = H or (un)substituted alkyl; m = 0-1; p = 0-1; n = 0-3 with provision when n = 2 the two C atoms may join through a double bond], or pharmaceutically acceptable salt forms thereof, are prepared and disclosed as modulators of MCP-1. Thus, e.g., II was prepared from benzyl (3S)-2-oxo-1-(4-oxocyclohexyl)-pyrrolidin-3-ylcarbamate

(preparation given) via a reductive amination process followed by a substitution reaction with 4-chloro-6-(trifluoromethyl)quinzazoline (preparation given). I were determined to be active (IC50 of 30 μM or less) in the antagonism of MCP-1 binding to human peripheral blood mononuclear cells. As modulators of MCP-1, I should be useful in the treatment of rheumatoid **arthritis**, multiple sclerosis, atherosclerosis and **asthma.**

IT **847998-74-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclic derivs. with chemokine receptor activity)

RN 847998-74-7 HCAPLUS

CN 2-Pyrrolidinone, 1-[trans-4-[(1,1-dimethylethyl)amino]cyclohexyl]-3-[[6-(1,1-dimethylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:701975 HCAPLUS
DOCUMENT NUMBER: 141:225304
TITLE: Preparation of cyclohexyl-substituted lactams as cytokine receptor modulating agents
INVENTOR(S): Cherney, Robert J.; Carter, Percy; Duncia, John V.; Gardner, Daniel S.; Santella, Joseph B.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071460	A2	20040826	WO 2004-US4418	20040211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, ML, MR, NE, SN, TD, TG

US 2004186140	A1	20040923	US 2004-776828	20040211
EP 1606255	A2	20051221	EP 2004-710294	20040211

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2003-446850P	P	20030212
	WO 2004-US4418	W	20040211

OTHER SOURCE(S): MARPAT 141:225304

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclohexyl-substituted lactams I [A = (un)substituted saturated or partially saturated cycloalkyl or heterocycloalkyl group with 3-8 atoms; E = S(:O)pCHR3, CHR3NR3, C(:O)NR3, N(R3)C(:O)NR3, SO2N(R3), N(R3)SO2N(R3); G = (CHR10)n; J = CH2CH2, CH:CH un(substituted) with (R13)s; R1, R2 = (un)substituted aryl or heteroaryl ring; R3 = H, alkyl; R10 = H, (un)substituted alkyl (two R10 groups may together comprise a carbonyl group); R11, R12 (independently) = H, (un)substituted alkyl, aralkyl, heteroaralkyl, ε-hydroxyalkyl, ε-mercaptoalkyl, ε-alkoxyalkyl, etc.; R13 = H, (un)substituted alkyl; X = O, S; Z = bond, (un)substituted aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminosulfonyl, aminosulfonylamino, carbonylamino, oxycarbonylamino, aminocarbonyloxy, alkenediyl, methylene, etc.; m = 0-1; n = 0-3; s = 0-1] such as II are prepared as modulators of cytokine activity for the treatment of diseases associated with cytokines and their receptors such as **inflammation**, osteo- and rheumatoid **arthritis**, **autoimmune** diseases, **HIV** infection, **inflammatory bowel disease**, **asthma**, multiple sclerosis, and atherosclerosis. E.g., 1,4-cyclohexanedione mono(ethylene ketal) is lithiated and acylated with Et cyanoformate, reductively aminated with (S)-α-methylbenzylamine, subjected to reduction with lithium aluminum hydride followed by hydrogenolysis with palladium hydroxide and protection with Cbz anhydride to yield nonracemic III. E.g., III undergoes substitution at the primary carbon with 4-bromophenyl disulfide and tributylphosphine followed by oxidation with mCPBA, Stille methylation of the p-bromophenyl moiety, hydrogenolysis of the Cbz protecting group, acylation with N-Cbz-L-methionine, and S-methylation and cyclization with Me iodide and cesium carbonate to yield IV. E.g., IV undergoes acid-catalyzed deketalization, titanium-mediated Meerwein-Pondorff-Verley reduction with isopropylamine (giving a mixture of both epimers at the amine center), N-methylation with formaldehyde and sodium triacetoxyborohydride, hydrogenolysis of the Cbz protecting group on the aminopyrrolidinone, and acylation with 3-trifluoromethylbenzoic acid and HATU to yield II. The compds. are modulators of chemokine receptor activity (no data). In addition, methods of halolactamization and dehalogenation and reagents appropriate for such transformations are claimed.

IT **746669-36-3P 746669-37-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as **inflammation**, rheumatoid **arthritis**, **asthma**, multiple sclerosis, and atherosclerosis)

RN 746669-36-3 HCAPLUS

CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-

yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-37-4 HCAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-tricyclo[3.3.1.13,7]dec-1-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:654775 HCAPLUS
DOCUMENT NUMBER: 141:190807
TITLE: Process for preparing pyrrolotriazine kinase inhibitors
INVENTOR(S): Chen, Bang-Chi; Zhao, Rulin; Sundeen, Joseph Edward; Leftheris, Katerina; Hynes, John; Wrobleski, Stephen T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157846	A1	20040812	US 2004-773002	20040205
CA 2515218	AA	20040826	CA 2004-2515218	20040205
WO 2004072030	A2	20040826	WO 2004-US3223	20040205
WO 2004072030	A3	20041028		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1590335	A2	20051102	EP 2004-708546	20040205

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2003-445224P	P	20030205
	WO 2004-US3223	W	20040205

OTHER SOURCE(S): CASREACT 141:190807; MARPAT 141:190807

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB An improved process for the preparation of certain pyrrolotriazine compds. such as I [R1, R2 = H, alkyl; R3 = H, alkyl, halo, CN, etc.; R4-R6 = H, alkyl, aryl, heteroaryl; n = 0-3; R7, R8 = H, alkyl, alkenyl, cycloalkyl, aryl, etc.; or NR7R8 = (un)substituted heterocyclyl, heteroaryl] is disclosed. Thus, reacting II [R4, R5 as above] with HO2CC(O)CHXR6 [X = a leaving group; R6 = as above] followed by reacting the resulting pyrrolotriazine III with an alc., reacting the ester with a chlorinating agent, reacting IV [R = alkyl, aryl, heteroaryl; R4-R6 as above] with an aniline V [R1-R3 as above], and reacting VI with an amine NHR7R8 afforded the compound I. 59 Compds. I were prepared The compds. I exhibit utility as **p38** kinase inhibitors (no biol. data given).

IT **165245-96-5**, **p38** Kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(process for preparing pyrrolotriazine **p38** kinase inhibitors)

RN 165245-96-5 HCAPLUS

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **427877-67-6P 427877-68-7P 427877-69-8P**
427877-70-1P 427877-71-2P 427877-72-3P
427877-73-4P 427877-75-6P 427877-76-7P
427877-80-3P 427877-81-4P 427877-82-5P
427877-87-0P 427877-90-5P 427877-91-6P
427877-93-8P 427877-96-1P 427877-98-3P
427877-99-4P 427878-00-0P 427878-02-2P
427878-03-3P 427878-04-4P 427878-10-2P
427878-17-9P 427878-18-0P 427878-20-4P
427878-66-8P 738617-11-3P 738617-12-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparing pyrrolotriazine **p38** kinase inhibitors)

RN 427877-67-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 427877-68-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 427877-69-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 427877-70-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-71-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427877-72-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1,1-dimethylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-73-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-75-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-76-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-80-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-81-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-

piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-82-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-87-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-90-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 427877-91-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-93-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)



RN 427877-96-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 427877-98-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 427877-99-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 427878-00-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-fluoroethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-02-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-03-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)



RN 427878-04-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-10-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-1-cyano-2-phenylethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-17-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-18-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-20-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[1-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-66-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 738617-11-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 738617-12-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-2,5-dimethyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 738617-11-3
CMF C20 H24 N6 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



IT **427877-66-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(process for preparing pyrrolotriazine **p38** kinase inhibitors)
RN 427877-66-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531311 HCAPLUS
DOCUMENT NUMBER: 141:89122
TITLE: Preparation of C-6 modified indazolyl pyrrolotriazines as antiproliferative agents
INVENTOR(S): Vite, Gregory D.; Gavai, Ashvinikumar V.; Fink, Brian E.; Mastalerz, Harold; Kadow, John F.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054514	A2	20040701	WO 2003-US39542	20031212
WO 2004054514	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509650	AA	20040701	CA 2003-2509650	20031212
EP 1569937	A2	20050907	EP 2003-813396	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016755	A	20051025	BR 2003-16755	20031212
US 2004142931	A1	20040722	US 2003-736476	20031215

US 6916815	B2	20050712			
US 2005222153	A1	20051006	US 2005-143279		20050602
NO 2005002733	A	20050707	NO 2005-2733		20050607
PRIORITY APPLN. INFO.:			US 2002-433190P	P	20021213
			WO 2003-US39542	W	20031212
			US 2003-736476	A3	20031215

OTHER SOURCE(S): MARPAT 141:89122

GI



I



II

AB The title compds. [I; R = (un)substituted aryl, heterocyclyl; R1 = (un)substituted alkyl; R2 = H, (un)substituted alkyl, cycloalkyl, aryl, etc.; X = a bond, O, S, (un)substituted NH, etc.] and their pharmaceutically acceptable salts which inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents, were prepared E.g., a multi-step synthesis of (3S)-II.HCl, starting from 5-nitroindazole, was given. Preferred compds. I exhibit IC50 of < 5 μM in one or more of HER1, HER2 and HER4 assays. The compds. I are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. The pharmaceutical composition comprising the compound I is claimed.

IT **714971-01-4P 714971-02-5P 714971-05-8P 714971-07-0P 714971-08-1P 714971-12-7P 714971-23-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of C-6 modified indazolyl pyrrolotriazines as antiproliferative agents)

RN 714971-01-4 HCAPLUS

CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-

methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 3-(methylsulfonyl)propyl ester (9CI) (CA INDEX NAME)



RN 714971-02-5 HCAPLUS
CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 2-amino-2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 714971-05-8 HCAPLUS
CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 3-(4-hydroxy-1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 714971-07-0 HCAPLUS
CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (2R)-2-aminopropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714971-08-1 HCAPLUS
CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (2S)-2-aminopropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714971-12-7 HCAPLUS
CN 4-Morpholinecarboxylic acid, 3-[[[[[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714971-23-0 HCAPLUS
CN Acetamide, N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)

BR 2003012940	A	20050621	BR 2003-12940		20030718
JP 2005538989	T2	20051222	JP 2004-523256		20030718
NO 2005000072	A	20050203	NO 2005-72		20050106
US 2005124621	A1	20050609	US 2005-35248		20050113
PRIORITY APPLN. INFO.:			US 2002-397256P	P	20020719
			US 2003-447213P	P	20030213
			US 2003-623171	A1	20030718
			WO 2003-US22826	W	20030718

OTHER SOURCE(S): MARPAT 140:124558

GI



I

AB The present invention provides pyrrolo[2,1-f][1,2,4]triazine compds. I(Z = O, S, N, OH, Cl; when Z = O or S, R4 is absent; when Z = OH or Cl, both R4 and R5 are absent; when Z = N, R4 = H; X,Y = O, OCO, S, SO, SO2, CO, CO2, halo, NO2, CN, etc., or X and Y are absent; R1 = H, Me, OH, OMe, SH, SMe, halo, NO2,CN, etc.; R2,R3 = H, (substituted)alkyl, (substituted)alkenyl, (substituted)alkynyl, (substituted)aryl, (substituted)heterocyclo, etc.; when X = halo, NO2, or CN, R2 is absent; when Y = halo, NO2, or CN, R3 is absent; R5 = (unsubstituted)indole; R6 = H, (substituted)alkyl, (substituted)aryl, (substituted)heterocyclo, halo, etc.), and pharmaceutically acceptable salts thereof. I compds. inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1 (no data), thereby making them useful as anti-**cancer** agents. I compds. are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. Thus, many I (R1,R4,R6 absent; R3Y = Me; Z = O; R5 = 2-methyl-4-fluoro-1H-indol-5-yl; X = O; R2 = (substituted)alkyl, arylalkyl, etc.) were synthesized.

IT **649735-42-2P 649735-43-3P 649735-44-4P**
649735-45-5P 649735-46-6P 649735-47-7P
649735-48-8P 649735-49-9P 649735-50-2P
649735-51-3P 649735-52-4P 649735-53-5P
649735-54-6P 649735-55-7P 649735-56-8P
649735-57-9P 649735-58-0P 649735-59-1P
649735-61-5P 649735-62-6P 649735-63-7P
649735-64-8P 649735-65-9P 649735-67-1P
649735-68-2P 649735-69-3P 649735-70-6P
649735-71-7P 649735-72-8P 649735-73-9P
649735-74-0P 649735-75-1P 649735-76-2P
649735-77-3P 649735-78-4P 649735-79-5P
649735-80-8P 649735-81-9P 649735-82-0P
649735-83-1P 649735-86-4P 649735-87-5P
649735-88-6P 649735-89-7P 649735-90-0P
649735-91-1P 649735-92-2P 649735-93-3P
649735-94-4P 649735-95-5P 649735-96-6P
649735-97-7P 649735-98-8P 649735-99-9P
649736-00-5P 649736-01-6P 649736-02-7P
649736-03-8P 649736-04-9P 649736-05-0P



L17 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80847 HCAPLUS
DOCUMENT NUMBER: 140:124558
TITLE: Pyrrolotriazine inhibitors of kinases for use in treatment of diseases associated with growth factor receptor signal transduction
INVENTOR(S): Bhide, Rajeev; Cai, Zhen-wei; Qian, Ligang; Barbosa, Stephanie
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009784	A2	20040129	WO 2003-US22826	20030718
WO 2004009784	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492804	AA	20040129	CA 2003-2492804	20030718
US 2004063707	A1	20040401	US 2003-622593	20030718
US 6969717	B2	20051129		
US 2004072832	A1	20040415	US 2003-623171	20030718
US 6869952	B2	20050322		
EP 1534290	A2	20050601	EP 2003-765881	20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

649736-06-1P 649736-07-2P 649736-08-3P
649736-09-4P 649736-10-7P 649736-11-8P
649736-12-9P 649736-13-0P 649736-14-1P
649736-16-3P 649736-17-4P 649736-18-5P
649736-20-9P 649736-22-1P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrrolotriazine inhibitors of kinases for use in treatment of diseases associated with growth factor receptor signal transduction)

RN 649735-42-2 HCAPLUS
CN Sulfamide, [3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 649735-43-3 HCAPLUS
CN Methanesulfonamide, N-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 649735-44-4 HCAPLUS
CN 1,2-Propanediol, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-45-5 HCAPLUS
CN 1,2-Propanediol, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-46-6 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-47-7 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 649735-48-8 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-49-9 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-50-2 HCAPLUS
CN Ethanol, 2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649735-51-3 HCAPLUS
CN Methanesulfonamide, N-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 649735-52-4 HCAPLUS
CN 2-Butanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-4-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-53-5 HCAPLUS

CN 2-Butanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-4-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-54-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-[(2-methyl-1H-indol-5-yl)oxy]-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-55-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 649735-56-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-

methyl-6-[3-(4-pyridinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-57-9 HCAPLUS
CN 2-Butanamine, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N,N-dimethyl-4-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-58-0 HCAPLUS
CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649735-59-1 HCAPLUS
CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N-methyl- (9CI) (CA INDEX

NAME)



RN 649735-61-5 HCAPLUS
CN L-Alanine, N,N-dimethyl-, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-62-6 HCAPLUS
CN L-Leucine, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-63-7 HCAPLUS

CN L-Alanine, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-64-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-65-9 HCAPLUS
CN Methanesulfonamide, N-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 649735-67-1 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 649735-68-2 HCAPLUS
CN Sulfamide, N'-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 649735-69-3 HCAPLUS
CN 1H-Imidazole-1-ethanol, 2-ethyl-α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 649735-70-6 HCAPLUS

CN 1H-Imidazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 649735-71-7 HCAPLUS
CN 1H-Imidazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 649735-72-8 HCAPLUS
CN 1H-1,2,4-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 649735-73-9 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 649735-74-0 HCAPLUS
CN 2-Pyrrolidinone, 1-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 649735-75-1 HCAPLUS
CN 1-Propanol, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649735-76-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(2-bromoethoxy)-4-[(4-fluoro-2-methyl-1H-

indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649735-77-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(3,3-dimethoxypropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649735-78-4 HCAPLUS
CN 2-Propanone, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 649735-79-5 HCAPLUS
CN Sulfamide, N'-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 649735-80-8 HCAPLUS
CN Sulfamide, [2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 649735-81-9 HCAPLUS
CN Formamide, N-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 649735-82-0 HCAPLUS
CN Phosphonic acid, [3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]propyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 649735-83-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(methylsulfinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-86-4 HCAPLUS
CN 1H-1,2,4-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-87-5 HCAPLUS
CN 4H-1,2,4-Triazole-4-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-88-6 HCAPLUS
CN 1H-1,2,3-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-89-7 HCAPLUS
CN 2H-1,2,3-Triazole-2-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-90-0 HCAPLUS
CN 4H-1,2,4-Triazole-4-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-91-1 HCAPLUS
CN 1H-1,2,4-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-92-2 HCAPLUS
CN 1H-1,2,3-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-93-3 HCAPLUS
CN 2H-1,2,3-Triazole-2-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-94-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-(1H-indol-5-yloxy)-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-95-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-1H-indol-5-yl)oxy]-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-96-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-97-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(6-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-98-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-1H-indol-5-yl-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-99-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, 5-methyl-N-(2-methyl-1H-indol-5-yl)-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649736-00-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-(2,3-dimethyl-1H-indol-5-yl)-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649736-01-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 649736-02-7 HCAPLUS
CN 1-Propanamine, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 649736-03-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 649736-04-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(methylthio)ethoxy]- (9CI) (CA INDEX NAME)



RN 649736-05-0 HCAPLUS
CN Ethanamine, 2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 649736-06-1 HCAPLUS
CN 2-Pyrrolidinone, 1-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 649736-07-2 HCAPLUS
CN 2-Pentanone, 5-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649736-08-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 649736-09-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(6-methyl-2-pyridinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649736-10-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-11-8 HCAPLUS
CN Carbamic acid, [(1R)-1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-3-(methylsulfonyl)propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649736-12-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(2-thienyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 649736-13-0 HCAPLUS
CN 2-Butanone, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649736-14-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-[(2-methoxyethoxy)methoxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-16-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(2-fluoroethoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-17-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[2-(1,1-dioxido-4-thiomorpholinyl)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-18-5 HCAPLUS
CN 2-Pentanol, 5-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649736-20-9 HCAPLUS
CN Carbamic acid, [5-methyl-4-[(2-methyl-1H-indol-5-yl)oxy]pyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 649736-22-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(methylthio)propoxy]- (9CI) (CA INDEX NAME)



IT **649736-29-8P 649736-32-3P 649736-33-4P**
649736-37-8P 649736-40-3P 649736-41-4P
649736-42-5P 649736-44-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrrolotriazine inhibitors of kinases for use in treatment of diseases

associated with growth factor receptor signal transduction)

RN 649736-29-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 649736-32-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(3-bromopropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-33-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-phenoxy-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649736-37-8 HCAPLUS

CN 2-Propanone, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649736-40-3 HCAPLUS
CN L-Leucine, N-[(phenylmethoxy)carbonyl]-, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649736-41-4 HCAPLUS
CN L-Alanine, N-[(phenylmethoxy)carbonyl]-, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649736-42-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-6-[3-(methylsulfonyl)propoxy]-4-phenoxy- (9CI) (CA INDEX NAME)



RN 649736-44-7 HCAPLUS
CN Methanesulfonamide, N-[3-[(5-methyl-4-phenoxypyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80698 HCAPLUS
DOCUMENT NUMBER: 140:146173
TITLE: Preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases
INVENTOR(S): Bhide, Rajeev; Ruel, Rejean; Thibeault, Carl; L'heureux, Alexandre
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009601	A1	20040129	WO 2003-US22554	20030718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492665	AA	20040129	CA 2003-2492665	20030718

US 2004063707	A1	20040401	US 2003-622593		20030718
US 6969717	B2	20051129			
US 2004072832	A1	20040415	US 2003-623171		20030718
US 6869952	B2	20050322			
EP 1539763	A1	20050615	EP 2003-765754		20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005538990	T2	20051222	JP 2004-523591		20030718
US 2005124621	A1	20050609	US 2005-35248		20050113
NO 2005000417	A	20050217	NO 2005-417		20050125
PRIORITY APPLN. INFO.:			US 2002-397256P	P	20020719
			US 2003-447213P	P	20030213
			US 2003-623171	A1	20030718
			WO 2003-US22554	W	20030718

OTHER SOURCE(S): MARPAT 140:146173

GI



I

AB Title compds. I [Z = O, S, N, etc.; X, Y = O, OCO, S, etc.; R1 = H, CH3, OH, etc.; R2, R3 = H, (un)substituted alkyl, alkenyl etc.; R4 = (un)substituted 7-azaindolyl, e.g., F, Cl, Me; R5 = H, absent when Z = O, S; R6 = H, (un)substituted alkyl, aryl, etc.] and their pharmaceutically acceptable salts were prepared For example, electrophilic substitution of compound I [R1 = H; R2X = benzyloxy; R3Y = CH3; ZR5R6 = Cl] with 4-fluoro-5-hydroxy-7-azaindole, e.g., prepared from 4-chloro-1H-pyrrolo[2,3-b]pyridine in 6-steps, afforded compound I [R1 = H; R2X = benzyloxy; R3Y = CH3; ZR5R6 = 4-fluoro-7-azaindol-5-yloxy] in 80% yield. In VEGFR-2 and FGFR-1 kinase assays, 38-examples of compds. I exhibited IC50 values ranging from 0.001-10 μM. Of note, pyrrolotriazines I exhibited selective VEGFR-2 and FGFR-1 kinase inhibition (no data provided). Compds. I are claimed useful for the treatment of **cancer**, **inflammation**, **autoimmune** diseases.

IT **651743-83-8P 651743-84-9P 651743-88-3P**
651743-89-4P 651743-90-7P 651743-91-8P
651743-92-9P 651743-93-0P 651743-94-1P
651743-95-2P 651743-96-3P 651743-97-4P
651743-98-5P 651743-99-6P 651744-00-2P
651744-01-3P 651744-02-4P 651744-04-6P
651744-09-1P 651744-10-4P 651744-11-5P
651744-19-3P 651744-52-4P 651744-53-5P
651744-54-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)

RN 651743-83-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-(1H-

pyrrolo[2,3-b]pyridin-5-yloxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 651743-84-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 651743-88-3 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-89-4 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-90-7 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-91-8 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-92-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-

yl)oxy]-5-methyl-6-[(2R)-2-(phenylmethoxy)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-93-0 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-94-1 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651743-95-2 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2S)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 651743-96-3 HCAPLUS
CN Sulfamide, [2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 651743-97-4 HCAPLUS
CN Methanesulfonamide, N-[2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 651743-98-5 HCAPLUS
CN Methanesulfonamide, N-[2-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA

INDEX NAME)



RN 651743-99-6 HCAPLUS
CN 2-Propanamine, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-00-2 HCAPLUS
CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-01-3 HCAPLUS
CN Ethanamine, 2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-

methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 651744-02-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 651744-04-6 HCAPLUS
CN 2-Propanol, 1-[[5-methyl-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-09-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, 6-[(2R)-2-aminopropoxy]-N-(4-fluoro-

1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-10-4 HCAPLUS
CN Sulfamide, [2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 651744-11-5 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-19-3 HCAPLUS
CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-52-4 HCAPLUS
CN 2-Propanamine, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 651744-53-5 HCAPLUS
CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 651744-54-6 HCAPLUS
CN 2-Propanol, 1-[[5-methyl-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **651744-50-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)
RN 651744-50-2 HCAPLUS
CN 2-Propanol, 1-[[5-methyl-4-(methylsulfonyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **651744-24-0P 651744-28-4P 651744-29-5P**
651744-30-8P 651744-31-9P 651744-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)
RN 651744-24-0 HCAPLUS
CN 2-Propanol, 1-[[5-methyl-4-(methylthio)pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-28-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[(2R)-2-azidopropoxy]-5-methyl-4-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-29-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[(2R)-2-azidopropoxy]-4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-30-8 HCAPLUS
CN Carbamic acid, [2-[(5-methyl-4-phenoxypyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651744-31-9 HCAPLUS
CN Carbamic acid, [2-[[5-methyl-4-(methylthio)pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651744-32-0 HCAPLUS
CN Carbamic acid, [2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80644 HCAPLUS
DOCUMENT NUMBER: 140:146018
TITLE: Process for preparation of indolyloxypyrrolotriazines and their use as drugs.
INVENTOR(S): Bhide, Rajeev; Fan, Junying; Parlanti, Luca; Barbosa, Stephanie; Qian, Ligang; Cai, Zhen-wei; Gibson, Francis S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009542	A2	20040129	WO 2003-US22755	20030721
WO 2004009542	A3	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004077858	A1	20040422	US 2003-622280	20030718
US 6933386	B2	20050823		
CA 2492861	AA	20040129	CA 2003-2492861	20030721
EP 1554281	A2	20050720	EP 2003-765846	20030721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012648	A	20050802	BR 2003-12648	20030721
JP 2006502120	T2	20060119	JP 2004-523221	20030721
US 2005124621	A1	20050609	US 2005-35248	20050113

PRIORITY APPLN. INFO.:		
US 2002-397256P	P	20020719
US 2003-447213P	P	20030213
US 2003-622280	A	20030718



L17 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:841986 HCAPLUS
DOCUMENT NUMBER: 134:17506
TITLE: Preparation of pyrrolotriazines as kinases inhibitors for treating **inflammation**, **cancer**, and proliferative diseases
INVENTOR(S): Hunt, John T.; Bhide, Rajeev S.; Borzilleri, Robert M.; Qian, Ligang
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071129	A1	20001130	WO 2000-US13420	20000516
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373990	AA	20001130	CA 2000-2373990	20000516
EP 1183033	A1	20020306	EP 2000-930761	20000516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010482	A	20020423	BR 2000-10482	20000516
JP 2003500359	T2	20030107	JP 2000-619433	20000516
NZ 516292	A	20040130	NZ 2000-516292	20000516
AU 770377	B2	20040219	AU 2000-48524	20000516
TR 200103352	T2	20050321	TR 2001-200103352	20000516
US 6982265	B1	20060103	US 2000-573829	20000518
NO 2001005650	A	20011120	NO 2001-5650	20011120
ZA 2001009577	A	20030220	ZA 2001-9577	20011120
US 2006004007	A1	20060105	US 2005-190412	20050727

PRIORITY APPLN. INFO.:		
US 1999-135265P	P	19990521
US 2000-193727P	P	20000331
WO 2000-US13420	W	20000516
US 2000-573829	A3	20000518

US 2003-623171 A1 20030718
WO 2003-US22755 W 20030721

OTHER SOURCE(S): MARPAT 140:146018

GI



I



II

AB Title compds. [I; X, Y = O, O2C, S, SO, SO2, CO, CO2, NR10, NR11CO, NR12CONR13, NR14CO2, NR15SO2, NR16SO2NR17, SO2NR18, CONR19, halo, NO2, cyano, null; R1, R6 = H; R2, R3 = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heteroaryl, heterocycloalkyl; R7-R19 = H, (substituted) alkyl, aryl, heteroaryl, heterocyclyl; R43 = H, F, Cl, Me; n = 0-2; R44 = H, Me; with provisos], were prepared in a 6-step procedure starting from pyrrolotriazinecarboxylates (II; R50 = alkyl, aryl; X1 = halo). Thus, Et 4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate (preparation given) was stirred with NaOEt in EtOH at 0° for 1 h to give 98% Et 4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate. The latter was stirred with MeMgBr in THF/Et2O at 0° for 4 h to give 100% 2-(4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)propan-2-ol. This was stirred with H2O2/BF3.Et2O in CH2Cl2 at -3° to -40° to give 76% 4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol. Benzylation of the latter with PhCH2Br/K2CO3 in DMF gave 6-benzyloxy-4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazine. Reflux of this with 1N HCl in EtOH gave 6-benzyloxy-4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine. This was added to a mixture prepared from 4-fluoro-2-methyl-1H-indol-5-ol and NaH in DMF at -20° followed by warming to room temperature to give 95% 6-benzyloxy-4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1f][1,2,4]triazine. Stirring of the latter with ammonium formate and Pd/C in DMF at room temperature for 2 h gave 64% 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol.

IT **649736-29-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of indolyloxypyrrolotriazines and their use as drugs)

RN 649736-29-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)

OTHER SOURCE(S): MARPAT 134:17506
GI



I



II

AB Title compds. [I; X, Y independently = O, OCO, S, SO, SO2, CO, CO2, NH, NHCO, NHCONH, bond; Z = O, S, N, CH; R1 = H, CH3, OH, OCH3, SH, SCH3, NH2, CO2H, NO2, CN, halo; R2, R3 independently = H, alkyl, alkenyl, alkynyl, aryl, heterocyclo; R4, R5 independently = H, alkyl, aryl, heterocyclo; R4-R5 = monocyclic 5-7 membered cyclic ring, bicyclic 7-11 membered cyclic ring; R6 = H, alkyl, aryl, heterocyclo, halo], enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, carriers, and solvates, which inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2 and produce **antiangiogenic** effect, are prepared Title compds. I are useful as anti-**cancer** agents, **antiinflammatories** and agents for the treatment of diseases associated with signal transduction pathways operating through growth factor receptors. Thus, the title compound II was prepared

IT **310443-09-5P 310443-13-1P 310443-35-7P**
310443-39-1P 310443-40-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrrolotriazines as kinases inhibitors useful in treating **inflammation**, **cancer**, and proliferative diseases)

RN 310443-09-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-bromo-2-fluorophenyl)amino]-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 310443-13-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 310443-35-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-N-[3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-39-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methoxyphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-40-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



IT **310442-35-4P 310442-50-3P 310442-52-5P**
310442-57-0P 310442-84-3P 310443-08-4P
310443-10-8P 310443-11-9P 310443-12-0P
310443-24-4P 310443-25-5P 310443-27-7P
310443-34-6P 310443-36-8P 310443-37-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolotriazines as kinases inhibitors useful in treating **inflammation**, **cancer**, and proliferative diseases)
RN 310442-35-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310442-50-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-[(butylamino)sulfonyl]phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-52-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-(acetylamino)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-57-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-84-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[6-(acetylamino)-3-pyridinyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310443-08-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 310443-10-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromo-2-fluorophenyl)amino]-5-methoxy-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-11-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromo-2-fluorophenyl)amino]-5-methoxy-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-12-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methoxy-4-[(6-methoxy-3-pyridinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 310443-24-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-5-[[[2-(4-morpholinyl)ethyl]amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methyl-, methyl

ester (9CI) (CA INDEX NAME)



RN 310443-25-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-2-oxo-5-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]-1H-indol-3-yl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310443-27-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-5-[[(2-hydroxyethyl)amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310443-34-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-36-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-37-9 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methyl-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)



IT **310444-73-6P 310444-74-7P 310444-85-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolotriazines as kinases inhibitors useful in treating **inflammation**, **cancer**, and proliferative diseases)
RN 310444-73-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-74-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-methanol, 4-[[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-85-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-phenoxy-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)



IT **310443-59-5P 310443-60-8P 310443-61-9P**
310443-62-0P 310443-63-1P 310443-70-0P
310443-71-1P 310443-72-2P 310443-73-3P
310443-76-6P 310443-77-7P 310443-78-8P
310443-79-9P 310443-80-2P 310443-81-3P
310443-82-4P 310443-83-5P 310443-88-0P
310443-93-7P 310443-94-8P 310443-98-2P

310444-00-9P 310444-01-0P 310444-03-2P
310444-05-4P 310444-08-7P 310444-17-8P
310444-18-9P 310444-20-3P 310444-21-4P
310444-24-7P 310444-25-8P 310444-26-9P
310444-29-2P 310444-30-5P 310444-33-8P
310444-37-2P 310444-39-4P 310444-41-8P
310444-49-6P 310444-61-2P 310444-62-3P
310444-63-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolotriazines as kinases inhibitors useful in treating **inflammation**, **cancer**, and proliferative diseases)

RN 310443-59-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N,5-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-60-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-61-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-62-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N-[[[3-(dimethylamino)propyl]amino]carbonyl]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 310443-63-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-70-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-71-1 HCAPLUS
CN Urea, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-72-2 HCAPLUS
CN Urea, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-73-3 HCAPLUS
CN Urea, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-N'-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)



RN 310443-76-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-77-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(1H-1,2,3-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-78-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(2H-1,2,3-triazol-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-79-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-80-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(2-methyl-1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-81-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)



RN 310443-82-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N,5-dimethyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-83-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(6-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-88-0 HCAPLUS
CN 4-Morpholinebutanamide, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)



RN 310443-93-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromophenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-94-8 HCAPLUS
CN Propanamide, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 310443-98-2 HCAPLUS
CN 4-Morpholinepropanesulfonamide, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)



RN 310444-00-9 HCAPLUS
CN 4-Morpholinebutanamide, N-[4-[5-(aminosulfonyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)



RN 310444-01-0 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-methyl-1-piperazinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 310444-03-2 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-morpholinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 310444-05-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-ethyl-3-hydroxyphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-08-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-hydroxy-4-(1-methylethyl)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-17-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-butyl-3-hydroxyphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-18-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(3-hydroxy-4-propylphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-20-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-21-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-24-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-ethyl-3-hydroxyphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-25-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromo-3-hydroxyphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-26-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(2H-1,2,3-triazol-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-29-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-30-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-33-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-37-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-39-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[4-(dimethylamino)butyl]-4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-41-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-49-6 HCAPLUS
CN Phenol, 2-methyl-5-[[5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 310444-61-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-(3-bromophenyl)-5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]- (9CI) (CA INDEX NAME)



RN 310444-62-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-(4-bromo-2-fluorophenyl)-5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]- (9CI) (CA INDEX NAME)



RN 310444-63-4 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d stat que
L5              STR
```









S @32







N @33 C @34




```
VAR G1=CH/11
VAR G2=ME/14/17/X/CN/NH2
VAR G3=CH/19
VAR G4=CH3/OH/17/SH/23/26/N/X/CN
VAR G5=66/32/33/34
VAR G20=O/S/N/26/X/CN/AK/CY
NODE ATTRIBUTES:
NSPEC   IS RC     AT  34
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  33

STEREO ATTRIBUTES: NONE
L7          533 SEA FILE=REGISTRY SSS FUL L5
L8          350 SEA FILE=REGISTRY ABB=ON  PLU=ON  P38/BI
L9          128 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND KINASE
L10          47 SEA FILE=REGISTRY ABB=ON  PLU=ON  (MITOGEN(W)ACTIVATED OR
                MAP)(L)KINASE(L)(P38 OR P(W)38)
L11          18 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L12       32869 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 OR L10 OR P38 OR P(W)38 OR
                MAP(2A)KINASE OR MITOGEN(W)ACTIVATED
L13           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND L12
L14          13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND (PAIN OR ?ACHE? OR
                ?EDEM? OR ?ANALGES? OR ?FEVER? OR ?IMMUNE? OR HIV? OR HTLV OR
                ?CANCER? OR ?NEOPLAS? OR ?MALIG? OR ?TUMOR? OR ?PROLIVER? OR
                ?ANGIOGEN? OR ?NEURODE? OR ?VIRAL? OR ?INFLAM? OR ?ASTHM? OR
                ?DIABET? OR (BLOOD OR BLD)(W)SUGAR OR BOWEL(W)DISEASE)
L15           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND (?PULMON? OR ?OSTEOPOR
                ? OR BONE(W)LOSS OR ?DEMENT? OR ?SENIL? OR ?ALZHEM? OR ?PSORI?
                OR ?ARTHRI? OR ?GOUT?)
L16           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 AND (L14 OR L15)
L17          10 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L13 OR L14 OR L15) NOT L16
```

L18 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 NOT (L16 OR L17)

=> d ibib abs hitstr l18 1-4

L18 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1350723 HCAPLUS
DOCUMENT NUMBER: 144:88323
TITLE: Processes for preparation of 5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one derivatives as intermediates of pyrrolo[2,1-f][1,2,4]triazine protein tyrosine kinase inhibitors
INVENTOR(S): Crispino, Gerard; Barbosa, Stephanie; Fan, Junying; Cai, Zhen-Wei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288289	A1	20051229	US 2005-165875	20050624
US 2005288290	A1	20051229	US 2005-167043	20050624
US 2006004006	A1	20060105	US 2005-167049	20050624
WO 2006004636	A2	20060112	WO 2005-US22682	20050628

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2006004833	A2	20060112	WO 2005-US23099	20050628

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2006004884	A2	20060112	WO 2005-US23198	20050628

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-583459P P 20040628
US 2004-612563P P 20040923

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is directed to intermediates (I) (Ra, Rb = Me, Et, Pr), (II) (P = H, protecting group), and (III) (P = protecting group, L = leaving group) that are useful for preparing 6-hydroxy-5-methyl-4-phenoxypyrrolo[2,1-f][1,2,4]triazines (IV) (R2 = H, halogen, cyano, NO2, OR5, NR6R7, each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, or heterocycloalkyl; R5, R6, R7 = H, alkyl, cycloalkyl, aryl, or heteroaryl; P = protecting group). Processes for preparing such intermediates involve, e.g. contacting the carbinols I with an acid in the presence of a peroxide to give II (P = H). Thus, 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid Et ester in THF was treated with methylmagnesium bromide in THF at <35°, kept at 25-45° until the reaction was complete, cooled to 0°, and quenched by adding aqueous NH4Cl solution to give, after workup, 6-(1-Hydroxy-1-methylethyl)-5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one (V). A mixture of V, 50% aqueous H2O2 solution, and THF was treated with a precooled solution of methanesulfonic acid in H2O at -5° to -0.7° in an ice/acetone bath, stirred at -2° for 95 min, quenched by adding a cooled solution of H2O, NaHSO3, and 28% aqueous NH4OH solution over 40 min at 15-20°, and stirred at room temperature for 20 min to give, after workup, 75.9% II (P = H). A mixture of II (P = H), diisopropylethylamine, and THF was cooled to 0-10°, treated with pivaloyl chloride at <20°, and stirred until the reaction was complete to give, after workup, II (R = pivaloyl) which was heated with POCl3 and diisopropylethylamine in MeCN at 85-90° for 4 h to give, after workup and silica gel flash chromatog., 78% III (P = pivaloyl, L = Cl). III (P = pivaloyl, L = Cl) was stirred with 2-fluoro-4-nitrophenol and K2CO3 in DMF at room temperature for 24 h to give, after workup and silica gel flash chromatog., 4-(2-fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate which was converted into 1-[3-fluoro-4-[(6-methoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]-3-(2-phenylacetyl)thiourea (VI) in 4 steps.

IT **872206-52-5P**, 4-(2-Fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate **872206-68-3P**, 4-(2-Fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate **872206-70-7P**, 4-(4-Amino-2-fluorophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate **872206-79-6P**, Ethyl 4-(2-fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate **872206-82-1P**, Ethyl 4-(4-amino-2-fluorophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; processes for preparation of 5-methyl-3H-pyrrolo[2,1-

f][1,2,4]triazin-4-one derivs. as intermediates of pyrrolo[2,1-f][1,2,4]triazine protein tyrosine kinase inhibitors)

RN 872206-52-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 872206-68-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 872206-70-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 872206-79-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 872206-82-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT **872206-41-2P**, N-[3-Fluoro-4-[(6-methoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]-N'-(2-phenylacetyl)thiourea **872206-62-7P**, 1-[3-Fluoro-4-[(6-methoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]-3-[2-(4-fluorophenyl)acetyl]thiourea **872206-66-1P**, 4-[2-Fluoro-4-[N'-[2-(4-fluorophenyl)acetyl]ureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate **872206-75-2P**, 4-[2-Fluoro-4-[N'-[2-(4-fluorophenyl)acetyl]thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate **872206-77-4P**, Ethyl 4-[2-fluoro-4-[N'-[2-(4-fluorophenyl)acetyl]thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate **872206-84-3P** **872206-88-7P**, 4-[2-Fluoro-4-[N'-[2-(4-fluorophenyl)acetyl]thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate **872206-92-3P**, 4-[2-Fluoro-4-[3-(2-phenylacetyl)thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(processes for preparation of 5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one derivs. as intermediates of pyrrolo[2,1-f][1,2,4]triazine protein tyrosine kinase inhibitors)

RN 872206-41-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 872206-62-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 872206-66-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 872206-75-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 872206-77-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 872206-84-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 872206-88-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 872206-92-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



L18 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1024924 HCAPLUS
DOCUMENT NUMBER: 143:460081
TITLE: New dual inhibitors of EGFR and HER2 protein tyrosine kinases
AUTHOR(S): Fink, Brian E.; Vite, Gregory D.; Mastalerz, Harold; Kadow, John F.; Kim, Soong-Hoon; Leavitt, Kenneth J.; Du, Karen; Crews, Donald; Mitt, Toomas; Wong, Tai W.; Hunt, John T.; Vyas, Dolatrai M.; Tokarski, John S.
CORPORATE SOURCE: Departments of Oncology Chemistry, Discovery Biology, and Computer Aided Drug Design, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4774-4779
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A novel series of dual EGFR and HER2 inhibitors based on the pyrrolo[2,1-f][1,2,4]triazine nucleus is described. A general route toward their synthesis, which enables functionalization at multiple sites, was developed. Biol. evaluation in enzymic and cell-based assays has identified a series of C(6) carbamates with potent biochem. and cellular activities.

IT **869067-04-9P 869067-05-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrrolotriazines as dual inhibitors of EGFR and HER2 protein tyrosine kinases)

RN 869067-04-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 869067-05-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:130304 HCAPLUS
DOCUMENT NUMBER: 142:392380
TITLE: Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors
AUTHOR(S): Borzilleri, Robert M.; Cai, Zhen-Wei; Ellis, Christopher; Fargnoli, Joseph; Fura, Aberra; Gerhardt, Tracy; Goyal, Bindu; Hunt, John T.; Mortillo, Steven; Qian, Ligang; Tokarski, John; Vyas, Viral; Wautlet, Barri; Zheng, Xioping; Bhide, Rajeev S.
CORPORATE SOURCE: Departments of Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1429-1433
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A versatile synthesis of the suitably functionalized pyrrolo[2,1-f][1,2,4]triazine nucleus is described. SAR at the C-5 and C-6 positions of the 4-(3-hydroxy-4-methylphenylamino)pyrrolo[2,1-f][1,2,4]triazine template led to compds. with good in vitro potency against VEGFR-2 kinase. Glucuronidation of the phenol group is mitigated by incorporation of a

basic amino group on the C-6 side chain of the pyrrolotriazine nucleus.

IT **310443-70-0P 310444-05-4P 310444-08-7P**
310444-18-9P 310444-26-9P 310444-29-2P
310444-37-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors)

RN 310443-70-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-05-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-ethyl-3-hydroxyphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-08-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-hydroxy-4-(1-methylethyl)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-18-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(3-hydroxy-4-propylphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-26-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(2H-1,2,3-triazol-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 310444-29-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-37-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



IT **649736-33-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors)
RN 649736-33-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-phenoxy-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:777390 HCAPLUS
DOCUMENT NUMBER: 139:292275
TITLE: Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
INVENTOR(S): Godfrey, Jollie Duaine; Hynes, John; Dyckman, Alaric J.; Leftheris, Katerina; Shi, Zhongping; Wrobleski, Stephen T.; Doubleday, Wendel William; Grosso, John A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 36,293.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003186982	A1	20031002	US 2002-289010	20021106
US 6867300	B2	20050315		
US 2003069244	A1	20030410	US 2001-36293	20011107
US 6670357	B2	20031230		
ZA 2003003786	A	20040816	ZA 2003-3786	20030515
US 2004229877	A1	20041118	US 2003-696178	20031029
CA 2505365	AA	20040527	CA 2003-2505365	20031103
WO 2004043912	A2	20040527	WO 2003-US35220	20031103
WO 2004043912	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1562949	A2	20050817	EP 2003-781756	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016056	A	20050927	BR 2003-16056	20031103
US 2005107462	A1	20050519	US 2004-19788	20041222

PRIORITY APPLN. INFO.:

US 2000-249877P	P	20001117
US 2001-310561P	P	20010807
US 2001-36293	A2	20011107
US 2002-289010	A	20021106
WO 2003-US35220	W	20031103

OTHER SOURCE(S): MARPAT 139:292275
GI



I

AB Methods are claimed for the preparation kinase inhibiting pharmaceutical compds. I (R1 = H, alkyl, aralkyl, OR1', CO2R1', CO2(OR1'), CO2NR1'NR1'' and SO3NR1'R1'' (R1' and R1'' = H, alkyl, aryl, aralkyl, heterocyclo or cycloalkyl or R1' + R1'' = cycloalkyl, aryl, heterocyclic group); A = R1X or E where X = O, OC(O), S, SO, SO2, CO, CO2, substituted NHCO2, NHSO2, NHCONH, SO2NH or CONH, halo, NO2, CN, nul; E is electron withdrawing group; R1 + A = substituted (un)saturated aromatic or heterocyclic ring; R2 = H, alkyl, alkenyl, alkynyl, (un)substituted aryl and heteroaryl, (un)substituted heterocyclo and cycloalkyl, (un)substituted carbonyl; R3 = H, OH, C1-6alkoxy, alkyl, C1-6perfluoroalkyl, OC1-6perfluoroalkyl, cycloalkyl, heterocyclo, aryl, aralkyl, acyl, carbalkoxy, carboxamido, CN, halo, (un)substituted amine, NO2, etc.; Z = O, S, N; R4 = substituted aryl; R5 = H, (un)substituted alkyl, etc.; R6 = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclo, aralkyl, amino, alc., aryl, carbalkoxy, acyl, carboxamido) or a pharmaceutically acceptable salt or solvate. The methods according to the invention use an amination process, in which a pyrrole is reacted with a haloamine, preferably chloramine. This step is followed by cyclization to form the pyrrolotriazine core. For example, N-cyclopropyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide was prepared by the amination of di-Et 3-methyl-1-pyrrole-2,4-dicarboxylate with chloramine followed by cyclization and addition of N-methoxy-3-amino-4-methylbenzamide hydrochloride, deprotection and reaction with cyclopropanamine.

IT **427877-66-5P 427878-02-2P 427878-42-0P**
427878-56-6P 427878-58-8P 427878-59-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolotriazine derivative as kinase inhibitor)

RN 427877-66-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-02-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-42-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-56-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-58-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-59-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



IT **427877-67-6P 427877-68-7P 427877-69-8P**
427877-70-1P 427877-71-2P 427877-72-3P
427877-73-4P 427877-75-6P 427877-76-7P

427877-80-3P 427877-81-4P 427877-82-5P
427877-87-0P 427877-90-5P 427877-91-6P
427877-93-8P 427877-96-1P 427877-98-3P
427877-99-4P 427878-00-0P 427878-03-3P
427878-04-4P 427878-10-2P 427878-17-9P
427878-18-0P 427878-20-4P 427878-27-1P
427878-28-2P 427878-29-3P 427878-30-6P
427878-31-7P 427878-33-9P 427878-35-1P
427878-36-2P 427878-37-3P 427878-38-4P
427878-44-2P 427878-45-3P 427878-46-4P
427878-47-5P 427878-48-6P 427878-49-7P
427878-52-2P 427878-53-3P 427878-54-4P
427878-55-5P 427878-60-2P 427878-61-3P
427878-62-4P 427878-63-5P 427878-64-6P
427878-65-7P 427878-66-8P 607738-96-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrrolotriazine derivative as kinase inhibitor)

RN 427877-67-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 427877-68-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 427877-69-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 427877-70-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-71-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427877-72-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1,1-dimethylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-73-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-75-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-76-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-80-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-81-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-82-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-87-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-90-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 427877-91-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-93-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-

[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylbutyl)-
(9CI) (CA INDEX NAME)



RN 427877-96-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenoxyethyl)-
(9CI) (CA INDEX NAME)



RN 427877-98-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA
INDEX NAME)



RN 427877-99-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 427878-00-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-fluoroethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-03-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)



RN 427878-04-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-10-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-1-cyano-2-phenylethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-17-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-18-0 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-20-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[1-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-27-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-28-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-29-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-propyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-30-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-methylpropyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-31-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-phenylethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-33-9 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 427878-35-1 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(4-cyanophenyl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-36-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(phenylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-37-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(4-cyanophenyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-38-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-44-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-

methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-45-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-46-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-47-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 427878-48-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-49-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 427878-52-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427878-53-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427878-54-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 427878-55-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[(ethylamino)carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-60-2 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[(phenylamino)carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-61-3 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-62-4 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-cyanophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-63-5 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-64-6 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-65-7 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-66-8 HCAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 607738-96-5 HCAPLUS

CN Methanesulfonic acid, trifluoro-, compd. with N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 427878-02-2
CMF C19 H22 N6 O3



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>